Alzheimer’s Patients Now Less Likely to Receive Biogen’s Aduhelm Treatment

Österreich Nachrichten Nachrichten

Alzheimer’s Patients Now Less Likely to Receive Biogen’s Aduhelm Treatment
Österreich Neuesten Nachrichten,Österreich Schlagzeilen
  • 📰 WSJhealth
  • ⏱ Reading Time:
  • 12 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 53%

Biogen’s Aduhelm, the Alzheimer’s drug that has faced resistance from insurers, will now only be available to a small pool of patients.

Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some doctors aren’t ready to prescribe it yet. Illustration: Jacob ReynoldsPeople with Alzheimer’s disease will be less likely to receive Biogen Inc.’s Aduhelm treatment because of thefor the drug in the face of restricted reimbursement by the U.S. Medicare program and other insurers.

The Cambridge, Mass., company said Tuesday that it is eliminating its “commercial infrastructure” for Aduhelm. It will maintain minimal resources to provide the drug for patients currently on the treatment at no cost.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

WSJhealth /  🏆 413. in US

Österreich Neuesten Nachrichten, Österreich Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Change at the top for Biogen after Alzheimer's drug flopsChange at the top for Biogen after Alzheimer's drug flopsBiogen is looking for a new CEO less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled. The company said Tuesday that current CEO Michel Vounatsos will continue to lead the company until his successor is appointed.
Weiterlesen »

Biogen CEO Michel Vounatsos to Step Aside After Alzheimer’s Drug StrugglesBiogen CEO Michel Vounatsos to Step Aside After Alzheimer’s Drug StrugglesMichel Vounatsos’s resignation comes as the company attempts to chart a new course following Medicare’s refusal to cover its new Alzheimer’s drug Aduhelm.
Weiterlesen »

Spirit will continue to pursue a merger with Frontier instead of JetBlueSpirit will continue to pursue a merger with Frontier instead of JetBlueSpirit says a deal with JetBlue isn’t likely to receive antitrust clearance.
Weiterlesen »

Why Women and Girls With Autism Spectrum Disorder Are Less Likely to Get a DiagnosisWhy Women and Girls With Autism Spectrum Disorder Are Less Likely to Get a DiagnosisLearn why women and girls experience autism differently, and why diagnosis is so important.
Weiterlesen »

A New Way to Measure What Actually Matters to PatientsA New Way to Measure What Actually Matters to PatientsThe same symptoms don't bother all patients equally, so why should they have to use the same measures? Here's what to try instead, writes bhaviorscientst
Weiterlesen »

David Birney, 'St. Elsewhere' Actor, Dead at 83David Birney, 'St. Elsewhere' Actor, Dead at 83'St. Elsewhere' and 'Bridget Loves Bernie' star David Birney has died at 83.
Weiterlesen »



Render Time: 2025-04-11 01:22:02